0.1073USD+7.30%Mkt Cap: 21.81M USDP/E: 0.17Last update: 2026-06-01
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer. The company's lead product is tilarginine th…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap21.81M USD
Enterprise Value14.84M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)149.05M USD
Revenue/Share—
Last Price0.1073 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees3
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)0.17
P/E (Forward)-0.08
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B1.89
EPS (TTM)0.64
EPS (Forward)-1.24
52W Range
0.015068% of range0.1500
52W High0.1500 USD
52W Low0.0150 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE2275.21%
ROA2071.28%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.05M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-12.63%
Net Debt-5.50M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio5.31
Quick Ratio4.82
Book Value/Sh0.0530 USD
Cash/Share0.0340 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.203.27M
Float97.07M
Insiders24.23%
Institutions3.71%
Short Interest
Short Ratio1.2d
Short % Float5.28%
Short % Out.3.90%
Shares Short2.12M
Short (prev mo.)2.66M
Technical
SMA 500.0782 (+37.1%)
SMA 2000.0378 (+184.0%)
Beta2.64
S&P 52W Chg27.94%
Avg Vol (30d)160.04K
Avg Vol (10d)62.02K
Technical Indicators
RSI (14)60.2
MACD0.0052
MACD Signal0.0072
MACD Hist.-0.0020
BB Upper0.1051 USD
BB Middle0.0985 USD
BB Lower0.0919 USD
BB Width13.32%
ATR (14)0.0083 USD
Vol Ratio (20d)0.14x